Vicky Makker, MD, Memorial Sloan Kettering Cancer Center

The Future of Endometrial Cancer Treatment

ByBradley J. Monk, MD, FACS, FACOG, University of Arizona, Creighton University, & Arizona Oncology Practice of US Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University

June 4th 2021

Experts give insight on what they are looking forward to in the endometrial cancer space.

A Look at Surgical Innovations in EC

ByBradley J. Monk, MD, FACS, FACOG, University of Arizona, Creighton University, & Arizona Oncology Practice of US Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University

June 4th 2021

Nicoletta Colombo, MD, PhD, reviews surgical advancements in endometrial cancer.

Novel Targets of Interest in EC

ByBradley J. Monk, MD, FACS, FACOG, University of Arizona, Creighton University, & Arizona Oncology Practice of US Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University

June 4th 2021

Experts in endometrial cancer comment on novel targets of interest that are currently being investigated.

Insight on Ongoing Trials in EC

ByBradley J. Monk, MD, FACS, FACOG, University of Arizona, Creighton University, & Arizona Oncology Practice of US Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University

June 4th 2021

Key opinion leaders take a look at the evolving treatment landscape in endometrial cancer, discussing ongoing trials in the space.

Incorporating Molecular Features into Choosing Adjuvant Therapy

ByBradley J. Monk, MD, FACS, FACOG, University of Arizona, Creighton University, & Arizona Oncology Practice of US Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University

June 4th 2021

Experts discuss the importance of incorporating molecular features into the selection of adjuvant treatment.

Therapeutic Sequencing in Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, University of Arizona, Creighton University, & Arizona Oncology Practice of US Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University

June 4th 2021

Experts in endometrial cancer comment on therapeutic sequencing in endometrial cancer.

Managing AEs With Pembrolizumab and Lenvatinib

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University

June 1st 2021

Key opinion leaders emphasize the importance of the management of adverse events in using pembrolizumab and lenvatinib.

Experience in Using Pembrolizumab + Lenvatinib in Advanced Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University

June 1st 2021

Experts give insight on their clinical use of pembrolizumab-lenvatinib. They highlight dose adjustments and the importance of the increased knowledge of adverse events.

A Discussion on the Study 309/KEYNOTE-775 Data

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University

May 25th 2021

Key opinion leaders discuss the presented data from Study 309/KEYNOTE-775, highlighting patient reported outcomes, safety, and dosing.

Results from Study 309/KEYNOTE-775

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University

May 25th 2021

Vicky Makker, MD, presents the results from Study 309/KEYNOTE-775, as well as key safety findings.

Novel Combinations for the Treatment of Advanced EC

ByShannon N. Westin, MD, MPH, FACOG,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center

May 19th 2021

Experts in gynecologic oncology discuss novel combination strategies for the treatment of advanced endometrial cancer.

Emerging Data From Ongoing IO Combination Trials in EC

ByShannon N. Westin, MD, MPH, FACOG,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center

May 19th 2021

Shannon N. Westin, MD, MPH, FACOG, and Vicky Makker, MD, comment on data from ongoing clinical trials presented at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer for the management of advanced endometrial cancer.

Study 309/KEYNOTE-775 Trial Design

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University

May 18th 2021

Vicky Makker, MD, walks through the trial design of Study 309/KEYNOTE-775.

Therapeutic Approaches in Endometrial Cancer

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University

May 18th 2021

Experts review optimal approaches to treatment in advanced endometrial cancer, touching on clinical trial data.

Patient Selection for Lenvatinib-Pembrolizumab for Advanced EC

ByShannon N. Westin, MD, MPH, FACOG,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center

May 12th 2021

Experts in gynecologic oncology share insights on patient selection for lenvatinib-pembrolizumab in advanced endometrial cancer and discuss therapeutic sequencing through multiple lines of therapy.

Impact of Lenvatinib-Pembrolizumab on Clinical Practice in Advanced EC

ByShannon N. Westin, MD, MPH, FACOG,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center

May 12th 2021

Vicky Makker, MD, and Shannon N. Westin, MD, MPH, FACOG, discuss their experiences using lenvatinib-pembrolizumab therapy for advanced endometrial cancer.

Biomarker Testing and Multidisciplinary Approaches in EC

ByBradley J. Monk, MD, FACS, FACOG, University of Arizona,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University

May 11th 2021

Key opinion leaders share their thoughts on biomarker testing and multidisciplinary approaches for endometrial cancer at their institutions globally.

Heterogeneity of Endometrial Cancer

ByBradley J. Monk, MD, FACOG, FACS, University of Arizona,Nicoletta Colombo, MD, PhD,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center,Domenica Lorusso, MD, PhD,David M. O'Malley, MD, The Ohio State University

May 11th 2021

Experts in gynecologic cancer discuss the heterogeneity of endometrial cancer..

Safety Results From KEYNOTE-775 Trial in Advanced EC

ByShannon N. Westin, MD, MPH, FACOG,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center

May 4th 2021

Vicky Makker, MD, reviews the safety profile of lenvatinib-pembrolizumab in advanced endometrial cancer from the phase 3 KEYNOTE-775/Study 309 trial and the management of common adverse events.

Phase 3 KEYNOTE-775 Trial in Advanced Endometrial Cancer

ByShannon N. Westin, MD, MPH, FACOG,Vicky Makker, MD, Memorial Sloan Kettering Cancer Center

May 4th 2021

Vicky Makker, MD, reviews the trial design and efficacy data for the open-label, randomized phase 3 KEYNOTE-775/Study 309 in patients with advanced endometrial cancer.